Table 5.
Associations with a change in D-dimer from before to after ESD in the subgroup analysis of midazolam users.
| Change in D-Dimer from before to after ESD | ||||||
|---|---|---|---|---|---|---|
| <1.0 (n = 83) | ≥1.0 (n = 20) | Univariate | OR | 95%CI | Multivariate | |
| Sex (male/female) | 57/26 | 17/3 | 0.177 | |||
| Age (years) | 68.7 ± 12.07 | 74.4 ± 7.23 | 0.034 a | 1.1 | 0.87–1.00 | 0.098 |
| Pathological examination (cancerous/non-cancerous) | 64/19 | 18/2 | 0.233 | |||
| ESD site (upper/lower) | 47/36 | 17/3 | 0.011 a | 1.2 | 0.25–6.71 | 0.818 |
| Maximum diameter of resected sample (mm) | 31 ± 14.8 | 36 ± 14.4 | 0.104 | |||
| WBC the day after ESD (109/L) | 7.9 ± 2.4 | 7.4 ± 2.5 | 0.364 | |||
| CRP the day after ESD (mg/dL) | 0.6 ± 0.9 | 1.2 ±1.5 | 0.068 | |||
| Thrombosis (n) | 18 | 3 | 0.391 | |||
| Hypertension (n) | 43 | 11 | 1.000 | |||
| Hyperlipidemia (n) | 23 | 4 | 0.423 | |||
| Diabetes mellitus (n) | 17 | 7 | 0.246 | |||
| Dialysis (n) | 1 | 1 | 0.335 | |||
| Antiplatelet drug use (n) | 9 | 3 | 1.000 | |||
| Anticoagulant use (n) | 8 | 0 | 0.206 | |||
| Procedure duration (min) | 113.3 ± 65.0 | 147.6 ± 65.9 | 0.028 a | 1.0 | 0.99–1.00 | 0.202 |
| Corrected midazolam doses | 2.3 ± 1.3 | 3.9 ± 1.8 | <0.001 a | 1.5 | 0.43–0.95 | 0.030 a |
| Total pentazocine Hydrochloride dose (mg) | 7.9 ± 8.2 | 1.1 ± 5.0 | <0.001 a | |||
| Total pethidine Hydrochloride dose (mg) | 20.5 ± 25.5 | 45.5 ± 25.0 | <0.001 a | 1.0 | 0.95–1.00 | 0.076 |
| Total haloperidol dose (mg) | 1.1 ± 2.2 | 2.6 ± 3.3 | 0.011 a | 1.0 | 0.77–1.28 | 0.959 |
Continuous value variables are described as mean ± standard deviation. WBC, white blood cell count; ESD, Endoscopic submucosal dissection; CRP, C-reactive protein. a: p < 0.05.